The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the annual general meeting to be held on Thursday 21 August 2025 at 16.00 at the company’s premises at Stortorget 1 in...
EQL has now taken the first step to establish itself in Germany and the Netherlands by recruiting key people with knowledge of the local markets who can identify, develop/in-license and launch nich...
EQL's key product Memprex[©] has now been licensed for sale in BeNeLux (Belgium, Netherlands, Luxemburg) with Goodlife Specialty BV, a leading local pharmaceutical company specialising in women’s h...
EQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in France, where it is to be provided to patients by EQL's license partner Laboratoires Majorelle...
Sales and operating profit growth, significant product acquisition completed, 11 new products, first deal outside Europe and graduation year passed
